Cantor Fitzgerald Reiterates Overweight Rating on Trevi Therapeutics (TRVI)

March 18, 2026 6:59 AM

Cantor Fitzgerald analyst Josh Schimmer reiterated an Overweight rating and $25.00 price target on Trevi Therapeutics (NASDAQ: TRVI).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found